Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

Thumbnail Image
Download
Name

Young_CDK7 inhibition.pdf

Size

2.61 MB

Format

Adobe PDF

Checksum (MD5)

80138cce0841b0cdeaf397c2c8a2825a

Author(s)
Chipumuro, Edmond
•
Marco, Eugenio
•
Christensen, Camilla L.
•
Zhang, Tinghu
•
Hatheway, Clark M.
•
Sharma, Bandana
•
Yeung, Caleb
•
Altabef, Abigail
•
Perez-Atayde, Antonio
•
Wong, Kwok-Kin
more
Date Issued
November 2014
Journal
Cell
Publisher
Elsevier
Citation
Chipumuro, Edmond; Marco, Eugenio; Christensen, Camilla L.; Kwiatkowski, Nicholas; Zhang, Tinghu; Hatheway, Clark M.; Abraham, Brian J.; et al. “CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer.” Cell 159, no. 5 (November 2014): 1126–1139. © 2014 Elsevier Inc.
Version
Author's final manuscript
Abstract
The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit MYC function as potential cancer therapy. Using a covalent inhibitor of cyclin-dependent kinase 7 (CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, we demonstrate downregulation of the oncoprotein with consequent massive suppression of MYCN-driven global transcriptional amplification. This response translated to significant tumor regression in a mouse model of high-risk neuroblastoma, without the introduction of systemic toxicity. The striking treatment selectivity of MYCN-overexpressing cells correlated with preferential downregulation of super-enhancer-associated genes, including MYCN and other known oncogenic drivers in neuroblastoma. These results indicate that CDK7 inhibition, by selectively targeting the mechanisms that promote global transcriptional amplification in tumor cells, may be useful therapy for cancers that are driven by MYC family oncoproteins.
MIT Department
Broad Institute of MIT and Harvard
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/108010
DOI of Published Version
https://doi.org/10.1016/j.cell.2014.10.024
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.